Official source Data mirrored from Centers for Medicare & Medicaid Services Open Payments · General Payments · CMS publication 2026-06-30 View official record

Covered recipient · General Payments record

BRADLEY CHRISTENSEN

Allopathic & Osteopathic Physicians Internal Medicine Hematology & Oncology

NPI
1720475874
CMS profile
4335568
Location
DALLAS, TX

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

Saved items

Saved only in this browser. No account or alerts.

Filter and download payment records

General Payments · PY2023 · Entire year

$4,478.89

90 records · 0 disputed

Summary and payment records

  • CMS publication 2026-06-30
Read the payment records

“Financial relationships do not necessarily indicate an improper relationship; the data is open to interpretation.”

— Centers for Medicare & Medicaid Services, Open Payments

A reported payment reflects a financial relationship a company disclosed. It does not indicate wrongdoing or a conflict of interest, and it says nothing about the quality of a provider's care.

These records are submitted to CMS and attested to by the reporting companies. CMS publishes them as reported; this site mirrors them without independent verification.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

How these totals are calculated
  • This total is the sum of the individual General Payments record amounts CMS published for the labeled program year(s); each record amount is used unmodified. The total itself is computed by this site. Nothing is estimated, weighted, or combined across categories.
  • General Payments only. Research and Ownership/Investment are separate datasets and are never summed with these figures; amounts are kept separate per program year.
  • Methodology & Data — sourcing, labeling, and limitations.

Provider summaries generated . CMS updates this data on an annual cycle, and corrections or successful disputes made at CMS may not yet appear here. The official CMS record is authoritative for the current state. View the official CMS record ↗

By nature of payment

PY2023 · entire year · sorted by reported total

Nature of paymentAmountRecords
Consulting Fee $2,310.00 1
Food and Beverage $1,987.90 87
Education $180.99 2

By paying entity

PY2023 · entire year · sorted by reported total

Page 2 of 2; records 51–90 of 90 matching records. This page contains 40 records (maximum 50), not the full filtered export. Use the CSV download for all matching records.

IndustryPayments · General Payments

BRADLEY CHRISTENSEN

NPI 1720475874 · CMS profile ID 4335568

Allopathic & Osteopathic Physicians / Internal Medicine / Hematology & Oncology

DALLAS, TX

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

General Payments, PY2023; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types

Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00

Page 2 of 2; records 51–90 of 90 matching records. This page contains 40 records (maximum 50), not the full filtered export.

Filtered page: https://industrypayments.org/provider/npi-1720475874?year=2023&recipient=provider&page=2#records-h

CMS source: https://openpaymentsdata.cms.gov/dataset/fb3a65aa-c901-4a38-a813-b04b00dfa2a9

Cite these filtered records

The citation includes this program year, filters, data edition, and page of results.

Plain
BRADLEY CHRISTENSEN, NPI 1720475874, CMS profile ID 4335568. General Payments, PY2023; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 2 of 2; records 51–90 of 90 matching records. This page contains 40 records (maximum 50), not the full filtered export. IndustryPayments. https://industrypayments.org/provider/npi-1720475874?year=2023&recipient=provider&page=2#records-h. Source: https://openpaymentsdata.cms.gov/dataset/fb3a65aa-c901-4a38-a813-b04b00dfa2a9.
APA 7
IndustryPayments. (2026). BRADLEY CHRISTENSEN, NPI 1720475874, CMS profile ID 4335568. General Payments, PY2023; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 2 of 2; records 51–90 of 90 matching records. This page contains 40 records (maximum 50), not the full filtered export. [Filtered data set page]. https://industrypayments.org/provider/npi-1720475874?year=2023&recipient=provider&page=2#records-h. Source: https://openpaymentsdata.cms.gov/dataset/fb3a65aa-c901-4a38-a813-b04b00dfa2a9.
Bluebook
BRADLEY CHRISTENSEN, NPI 1720475874, CMS profile ID 4335568, IndustryPayments, General Payments, PY2023; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types (Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00). Page 2 of 2; records 51–90 of 90 matching records. This page contains 40 records (maximum 50), not the full filtered export. Source: https://openpaymentsdata.cms.gov/dataset/fb3a65aa-c901-4a38-a813-b04b00dfa2a9. https://industrypayments.org/provider/npi-1720475874?year=2023&recipient=provider&page=2#records-h.

Centers for Medicare & Medicaid Services, Open Payments

Citation formats are provided for reference; check the requirements of your publication.

Payment records · PY2023

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

General Payments · PY2023 · Physicians and non-physician practitioners · CMS publication 2026-06-30

90 matching records · $4,478.89 reported total · 0 disputed

Nature of payment: All payment types

Records imported here (UTC).

Link to these filtered records · CMS source dataset ↗

Download all 90 matching records (CSV)

CSV includes CMS record IDs, source and publication dates, the data edition, and a link to these filters. Formula-like text cells are prefixed with an apostrophe for spreadsheet safety.

Showing records 51–90 of 90.

Paying entityAmountDate Nature of paymentDispute statusPublication flagsPublished Record IDSource
ADC Therapeutics America, Inc. $16.5607/19/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1053787135 CMS
Mirati Therapeutics, Inc. $19.4107/12/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1057988435 CMS
GlaxoSmithKline, LLC. $24.3007/11/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1001761368 CMS
Novartis Pharmaceuticals Corporation $25.3107/10/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 991524079 CMS
Incyte Corporation $22.1407/06/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1044720395 CMS
RECORDATI_RARE_DISEASES_INC. $19.7907/05/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1060351389 CMS
Seagen Inc. $18.1006/28/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 995756705 CMS
GENZYME CORPORATION $30.3406/26/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1050343835 CMS
AstraZeneca Pharmaceuticals LP $22.2706/22/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1014750723 CMS
SOBI, INC $2,310.0006/08/2023 Consulting Fee No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1038136139 CMS
AbbVie Inc. $33.9506/07/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 996441837 CMS
Incyte Corporation $24.5506/06/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1044720319 CMS
Blueprint Medicines Corporation $20.5706/01/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1051267355 CMS
Novartis Pharmaceuticals Corporation $33.7505/25/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 991524075 CMS
Karyopharm Therapeutics Inc. $20.4305/24/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1056897931 CMS
GENZYME CORPORATION $25.1405/23/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1050343823 CMS
Amgen Inc. $27.8705/22/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1019837559 CMS
PharmaEssentia USA Corporation $24.1205/16/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1059302771 CMS
Seagen Inc. $15.0905/15/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 995756591 CMS
Jazz Pharmaceuticals Inc. $20.4805/11/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1059096793 CMS
ADC Therapeutics America, Inc. $21.2405/10/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1053786977 CMS
Amgen Inc. $30.7105/08/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1019837563 CMS
Pharmacyclics LLC, An AbbVie Company $98.0005/08/2023 Education No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 998283709 CMS
AstraZeneca Pharmaceuticals LP $18.0305/04/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1012039695 CMS
MorphoSys, US Inc. $15.1904/26/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1060328095 CMS
AbbVie Inc. $28.3004/19/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 996441833 CMS
CTI BioPharma Corp. $24.1904/06/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1039688747 CMS
Takeda Pharmaceuticals U.S.A., Inc. $14.0703/30/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1055368999 CMS
GENZYME CORPORATION $29.2703/23/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1050343799 CMS
Blueprint Medicines Corporation $20.0803/22/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1051267275 CMS
Novartis Pharmaceuticals Corporation $20.0203/15/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 991524055 CMS
GlaxoSmithKline, LLC. $26.8803/13/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1001761377 CMS
Incyte Corporation $21.9603/09/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1044720083 CMS
Pharmacyclics LLC, An AbbVie Company $26.4802/17/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 998283707 CMS
Incyte Corporation $3.4102/16/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1044720047 CMS
Jazz Pharmaceuticals Inc. $30.5102/16/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1059096791 CMS
Incyte Corporation $24.4202/15/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1044720071 CMS
Adaptive Biotechnologies Corporation $32.6802/03/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1022978883 CMS
SOBI, INC $26.7701/26/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1038083541 CMS
Karyopharm Therapeutics Inc. $20.0401/18/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1056897923 CMS

By program year

All program years on this page · sorted by year

Program yearAmountRecords
PY2022 $289.70 14
PY2023 $4,478.89 90
PY2024 $11,128.41 72
PY2025 $15,213.64 37

Source & provenance

Dataset
CMS Open Payments — General Payments
Publisher of source data
Centers for Medicare & Medicaid Services
CMS publication date
2026-06-30
Program years on this page
2022, 2023, 2024, 2025
Source files and profile matching
Source files
Dataset page · Bulk file · PY2022 , PY2023 , PY2024 , PY2025
Generated from
OP_DTL_GNRL_PGYR2025_P06302026_06032026.csv

One page per canonical provider; split Profile_IDs are merged via Associated_Covered_Recipient_Profile_ID_1/_2 from the Covered Recipient Profile Supplement.

Corrections to the substance of a record route to CMS through its review-and-dispute process; errors in how this site mirrors or displays a record route to us. Both paths are described in Methodology & Data.

Research Payments

One row per program year and role, newest year first · amounts for the two roles are never added together

Program yearRoleAmountRecords
PY2025 Principal investigator $179,577.77 74

Research Payments are a separate CMS dataset, shown here separately and never added to General Payments. A research payment is often made to an institution, with this provider named as a principal investigator; each record states which role applies.

“If you are a physician who served as a principal investigator on a research study, you may see the payments associated with that research study listed under your name. This does not necessarily mean the payments are attributed to you. The dollar amount of the record corresponds to the total payment; the amounts are not attributed to each individual on the record.”

— Centers for Medicare & Medicaid Services, Open Payments Frequently Asked Questions, FAQ #12224

Research Payments records · PY2025

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

74 records in PY2025

Research Payments records (CSV)

RolePaying entityAmount DateRecipientStudy Dispute statusPublishedRecord ID
Principal investigator 1 Stemline Therapeutics Inc. $975.00 12/19/2025 Non-covered Recipient Entity
Baylor Research Institute
STML-401-0423 - A PHASE II MULTICENTER OPEN -LABEL TRIAL OF TAGRAXOFUSP (TAG) IN COMBINATION WITH VENETOCLAX AND AZACITIDINE (VEN/AZA) IN ADULTS WITH PREVIOUSLY UNTREATED CD123+ ACUTE MYELOID LEUKEMIA (AML) WHO ARE INELIGIBLE FOR INTENSIVE CHEMOTHERAPY No dispute reported 06/30/2026 1244112603
Principal investigator 1 Stemline Therapeutics Inc. $1,000.00 12/19/2025 Non-covered Recipient Entity
Baylor Research Institute
STML-401-0423 - A PHASE II MULTICENTER OPEN -LABEL TRIAL OF TAGRAXOFUSP (TAG) IN COMBINATION WITH VENETOCLAX AND AZACITIDINE (VEN/AZA) IN ADULTS WITH PREVIOUSLY UNTREATED CD123+ ACUTE MYELOID LEUKEMIA (AML) WHO ARE INELIGIBLE FOR INTENSIVE CHEMOTHERAPY No dispute reported 06/30/2026 1244112610
Principal investigator 1 Stemline Therapeutics Inc. $50.00 12/05/2025 Non-covered Recipient Entity
Baylor Research Institute
STML-401-0423 - A PHASE II MULTICENTER OPEN -LABEL TRIAL OF TAGRAXOFUSP (TAG) IN COMBINATION WITH VENETOCLAX AND AZACITIDINE (VEN/AZA) IN ADULTS WITH PREVIOUSLY UNTREATED CD123+ ACUTE MYELOID LEUKEMIA (AML) WHO ARE INELIGIBLE FOR INTENSIVE CHEMOTHERAPY No dispute reported 06/30/2026 1244112592
Principal investigator 1 Stemline Therapeutics Inc. $253.50 12/05/2025 Non-covered Recipient Entity
Baylor Research Institute
STML-401-0423 - A PHASE II MULTICENTER OPEN -LABEL TRIAL OF TAGRAXOFUSP (TAG) IN COMBINATION WITH VENETOCLAX AND AZACITIDINE (VEN/AZA) IN ADULTS WITH PREVIOUSLY UNTREATED CD123+ ACUTE MYELOID LEUKEMIA (AML) WHO ARE INELIGIBLE FOR INTENSIVE CHEMOTHERAPY No dispute reported 06/30/2026 1244112597
Principal investigator 1 Stemline Therapeutics Inc. $50.00 12/05/2025 Non-covered Recipient Entity
Baylor Research Institute
STML-401-0423 - A PHASE II MULTICENTER OPEN -LABEL TRIAL OF TAGRAXOFUSP (TAG) IN COMBINATION WITH VENETOCLAX AND AZACITIDINE (VEN/AZA) IN ADULTS WITH PREVIOUSLY UNTREATED CD123+ ACUTE MYELOID LEUKEMIA (AML) WHO ARE INELIGIBLE FOR INTENSIVE CHEMOTHERAPY No dispute reported 06/30/2026 1244112614
Principal investigator 1 Syndax Pharmaceuticals, Inc. $3,520.00 12/01/2025 Non-covered Recipient Entity
BAYLOR RESEARCH INSTITUTE
A PHASE 1, OPEN-LABEL, DOSE-ESCALATION, AND DOSE-EXPANSION STUDY TO EVALUATE SAFETY, TOLERABILITY, AND CLINICAL ACTIVITY OFSNDX-5613IN COMBINATION WITH INTENSIVE CHEMOTHERAPY IN PARTICIPANTS WITH NEWLY DIAGNOSED ACUTE MYELOID LEUKEMIAS HARBORING ALTERATIONS IN LYSINE-SPECIFIC METHYLTRANSFERASE 2A (KMT2A/MLL), NUCLEOPHOSMIN 1 (NPM1), AND NUCLEOPORIN 98 (NUP98) GENES No dispute reported 06/30/2026 1249050959
Principal investigator 1 Syndax Pharmaceuticals, Inc. $1,220.00 11/19/2025 Non-covered Recipient Entity
BAYLOR RESEARCH INSTITUTE
A PHASE 1, OPEN-LABEL, DOSE-ESCALATION, AND DOSE-EXPANSION STUDY TO EVALUATE SAFETY, TOLERABILITY, AND CLINICAL ACTIVITY OFSNDX-5613IN COMBINATION WITH INTENSIVE CHEMOTHERAPY IN PARTICIPANTS WITH NEWLY DIAGNOSED ACUTE MYELOID LEUKEMIAS HARBORING ALTERATIONS IN LYSINE-SPECIFIC METHYLTRANSFERASE 2A (KMT2A/MLL), NUCLEOPHOSMIN 1 (NPM1), AND NUCLEOPORIN 98 (NUP98) GENES No dispute reported 06/30/2026 1249050951
Principal investigator 1 Syndax Pharmaceuticals, Inc. $1,170.00 11/14/2025 Non-covered Recipient Entity
BAYLOR RESEARCH INSTITUTE
A PHASE 1, OPEN-LABEL, DOSE-ESCALATION, AND DOSE-EXPANSION STUDY TO EVALUATE SAFETY, TOLERABILITY, AND CLINICAL ACTIVITY OFSNDX-5613IN COMBINATION WITH INTENSIVE CHEMOTHERAPY IN PARTICIPANTS WITH NEWLY DIAGNOSED ACUTE MYELOID LEUKEMIAS HARBORING ALTERATIONS IN LYSINE-SPECIFIC METHYLTRANSFERASE 2A (KMT2A/MLL), NUCLEOPHOSMIN 1 (NPM1), AND NUCLEOPORIN 98 (NUP98) GENES No dispute reported 06/30/2026 1249050947
Principal investigator 1 Syndax Pharmaceuticals, Inc. $4,822.50 10/22/2025 Non-covered Recipient Entity
BAYLOR RESEARCH INSTITUTE
A PHASE 1, OPEN-LABEL, DOSE-ESCALATION, AND DOSE-EXPANSION STUDY TO EVALUATE SAFETY, TOLERABILITY, AND CLINICAL ACTIVITY OFSNDX-5613IN COMBINATION WITH INTENSIVE CHEMOTHERAPY IN PARTICIPANTS WITH NEWLY DIAGNOSED ACUTE MYELOID LEUKEMIAS HARBORING ALTERATIONS IN LYSINE-SPECIFIC METHYLTRANSFERASE 2A (KMT2A/MLL), NUCLEOPHOSMIN 1 (NPM1), AND NUCLEOPORIN 98 (NUP98) GENES No dispute reported 06/30/2026 1249050851
Principal investigator 1 Janssen Research & Development, LLC $950.00 10/13/2025 Non-covered Recipient Entity
BAYLOR SCOTT & WHITE RESEARCH INSTI
A First in Human Study of the MeninKMT2A MLL1 Inhibitor JNJ75276617 in Participants with Acute Leukemia No dispute reported 06/30/2026 1175403936
Principal investigator 1 Stemline Therapeutics Inc. $149.99 09/01/2025 Non-covered Recipient Entity
Baylor Research Institute
STML-401-0423 - A PHASE II MULTICENTER OPEN -LABEL TRIAL OF TAGRAXOFUSP (TAG) IN COMBINATION WITH VENETOCLAX AND AZACITIDINE (VEN/AZA) IN ADULTS WITH PREVIOUSLY UNTREATED CD123+ ACUTE MYELOID LEUKEMIA (AML) WHO ARE INELIGIBLE FOR INTENSIVE CHEMOTHERAPY No dispute reported 06/30/2026 1244112428
Principal investigator 1 Stemline Therapeutics Inc. $149.99 09/01/2025 Non-covered Recipient Entity
Baylor Research Institute
STML-401-0423 - A PHASE II MULTICENTER OPEN -LABEL TRIAL OF TAGRAXOFUSP (TAG) IN COMBINATION WITH VENETOCLAX AND AZACITIDINE (VEN/AZA) IN ADULTS WITH PREVIOUSLY UNTREATED CD123+ ACUTE MYELOID LEUKEMIA (AML) WHO ARE INELIGIBLE FOR INTENSIVE CHEMOTHERAPY No dispute reported 06/30/2026 1244112441
Principal investigator 1 Stemline Therapeutics Inc. $975.00 09/01/2025 Non-covered Recipient Entity
Baylor Research Institute
STML-401-0423 - A PHASE II MULTICENTER OPEN -LABEL TRIAL OF TAGRAXOFUSP (TAG) IN COMBINATION WITH VENETOCLAX AND AZACITIDINE (VEN/AZA) IN ADULTS WITH PREVIOUSLY UNTREATED CD123+ ACUTE MYELOID LEUKEMIA (AML) WHO ARE INELIGIBLE FOR INTENSIVE CHEMOTHERAPY No dispute reported 06/30/2026 1244112448
Principal investigator 1 Stemline Therapeutics Inc. $149.99 09/01/2025 Non-covered Recipient Entity
Baylor Research Institute
STML-401-0423 - A PHASE II MULTICENTER OPEN -LABEL TRIAL OF TAGRAXOFUSP (TAG) IN COMBINATION WITH VENETOCLAX AND AZACITIDINE (VEN/AZA) IN ADULTS WITH PREVIOUSLY UNTREATED CD123+ ACUTE MYELOID LEUKEMIA (AML) WHO ARE INELIGIBLE FOR INTENSIVE CHEMOTHERAPY No dispute reported 06/30/2026 1244112456
Principal investigator 1 Stemline Therapeutics Inc. $365.17 09/01/2025 Non-covered Recipient Entity
Baylor Research Institute
STML-401-0423 - A PHASE II MULTICENTER OPEN -LABEL TRIAL OF TAGRAXOFUSP (TAG) IN COMBINATION WITH VENETOCLAX AND AZACITIDINE (VEN/AZA) IN ADULTS WITH PREVIOUSLY UNTREATED CD123+ ACUTE MYELOID LEUKEMIA (AML) WHO ARE INELIGIBLE FOR INTENSIVE CHEMOTHERAPY No dispute reported 06/30/2026 1244112463
Principal investigator 1 Stemline Therapeutics Inc. $149.99 09/01/2025 Non-covered Recipient Entity
Baylor Research Institute
STML-401-0423 - A PHASE II MULTICENTER OPEN -LABEL TRIAL OF TAGRAXOFUSP (TAG) IN COMBINATION WITH VENETOCLAX AND AZACITIDINE (VEN/AZA) IN ADULTS WITH PREVIOUSLY UNTREATED CD123+ ACUTE MYELOID LEUKEMIA (AML) WHO ARE INELIGIBLE FOR INTENSIVE CHEMOTHERAPY No dispute reported 06/30/2026 1244112471
Principal investigator 1 Stemline Therapeutics Inc. $149.99 09/01/2025 Non-covered Recipient Entity
Baylor Research Institute
STML-401-0423 - A PHASE II MULTICENTER OPEN -LABEL TRIAL OF TAGRAXOFUSP (TAG) IN COMBINATION WITH VENETOCLAX AND AZACITIDINE (VEN/AZA) IN ADULTS WITH PREVIOUSLY UNTREATED CD123+ ACUTE MYELOID LEUKEMIA (AML) WHO ARE INELIGIBLE FOR INTENSIVE CHEMOTHERAPY No dispute reported 06/30/2026 1244112476
Principal investigator 1 Stemline Therapeutics Inc. $149.99 09/01/2025 Non-covered Recipient Entity
Baylor Research Institute
STML-401-0423 - A PHASE II MULTICENTER OPEN -LABEL TRIAL OF TAGRAXOFUSP (TAG) IN COMBINATION WITH VENETOCLAX AND AZACITIDINE (VEN/AZA) IN ADULTS WITH PREVIOUSLY UNTREATED CD123+ ACUTE MYELOID LEUKEMIA (AML) WHO ARE INELIGIBLE FOR INTENSIVE CHEMOTHERAPY No dispute reported 06/30/2026 1244112482
Principal investigator 1 Stemline Therapeutics Inc. $149.99 09/01/2025 Non-covered Recipient Entity
Baylor Research Institute
STML-401-0423 - A PHASE II MULTICENTER OPEN -LABEL TRIAL OF TAGRAXOFUSP (TAG) IN COMBINATION WITH VENETOCLAX AND AZACITIDINE (VEN/AZA) IN ADULTS WITH PREVIOUSLY UNTREATED CD123+ ACUTE MYELOID LEUKEMIA (AML) WHO ARE INELIGIBLE FOR INTENSIVE CHEMOTHERAPY No dispute reported 06/30/2026 1244112488
Principal investigator 1 Stemline Therapeutics Inc. $149.99 09/01/2025 Non-covered Recipient Entity
Baylor Research Institute
STML-401-0423 - A PHASE II MULTICENTER OPEN -LABEL TRIAL OF TAGRAXOFUSP (TAG) IN COMBINATION WITH VENETOCLAX AND AZACITIDINE (VEN/AZA) IN ADULTS WITH PREVIOUSLY UNTREATED CD123+ ACUTE MYELOID LEUKEMIA (AML) WHO ARE INELIGIBLE FOR INTENSIVE CHEMOTHERAPY No dispute reported 06/30/2026 1244112494
Principal investigator 1 Stemline Therapeutics Inc. $149.99 09/01/2025 Non-covered Recipient Entity
Baylor Research Institute
STML-401-0423 - A PHASE II MULTICENTER OPEN -LABEL TRIAL OF TAGRAXOFUSP (TAG) IN COMBINATION WITH VENETOCLAX AND AZACITIDINE (VEN/AZA) IN ADULTS WITH PREVIOUSLY UNTREATED CD123+ ACUTE MYELOID LEUKEMIA (AML) WHO ARE INELIGIBLE FOR INTENSIVE CHEMOTHERAPY No dispute reported 06/30/2026 1244112500
Principal investigator 1 Stemline Therapeutics Inc. $149.99 09/01/2025 Non-covered Recipient Entity
Baylor Research Institute
STML-401-0423 - A PHASE II MULTICENTER OPEN -LABEL TRIAL OF TAGRAXOFUSP (TAG) IN COMBINATION WITH VENETOCLAX AND AZACITIDINE (VEN/AZA) IN ADULTS WITH PREVIOUSLY UNTREATED CD123+ ACUTE MYELOID LEUKEMIA (AML) WHO ARE INELIGIBLE FOR INTENSIVE CHEMOTHERAPY No dispute reported 06/30/2026 1244112505
Principal investigator 1 Stemline Therapeutics Inc. $149.99 09/01/2025 Non-covered Recipient Entity
Baylor Research Institute
STML-401-0423 - A PHASE II MULTICENTER OPEN -LABEL TRIAL OF TAGRAXOFUSP (TAG) IN COMBINATION WITH VENETOCLAX AND AZACITIDINE (VEN/AZA) IN ADULTS WITH PREVIOUSLY UNTREATED CD123+ ACUTE MYELOID LEUKEMIA (AML) WHO ARE INELIGIBLE FOR INTENSIVE CHEMOTHERAPY No dispute reported 06/30/2026 1244112511
Principal investigator 1 Stemline Therapeutics Inc. $149.99 09/01/2025 Non-covered Recipient Entity
Baylor Research Institute
STML-401-0423 - A PHASE II MULTICENTER OPEN -LABEL TRIAL OF TAGRAXOFUSP (TAG) IN COMBINATION WITH VENETOCLAX AND AZACITIDINE (VEN/AZA) IN ADULTS WITH PREVIOUSLY UNTREATED CD123+ ACUTE MYELOID LEUKEMIA (AML) WHO ARE INELIGIBLE FOR INTENSIVE CHEMOTHERAPY No dispute reported 06/30/2026 1244112518
Principal investigator 1 Stemline Therapeutics Inc. $149.99 09/01/2025 Non-covered Recipient Entity
Baylor Research Institute
STML-401-0423 - A PHASE II MULTICENTER OPEN -LABEL TRIAL OF TAGRAXOFUSP (TAG) IN COMBINATION WITH VENETOCLAX AND AZACITIDINE (VEN/AZA) IN ADULTS WITH PREVIOUSLY UNTREATED CD123+ ACUTE MYELOID LEUKEMIA (AML) WHO ARE INELIGIBLE FOR INTENSIVE CHEMOTHERAPY No dispute reported 06/30/2026 1244112523
Principal investigator 1 Stemline Therapeutics Inc. $149.99 09/01/2025 Non-covered Recipient Entity
Baylor Research Institute
STML-401-0423 - A PHASE II MULTICENTER OPEN -LABEL TRIAL OF TAGRAXOFUSP (TAG) IN COMBINATION WITH VENETOCLAX AND AZACITIDINE (VEN/AZA) IN ADULTS WITH PREVIOUSLY UNTREATED CD123+ ACUTE MYELOID LEUKEMIA (AML) WHO ARE INELIGIBLE FOR INTENSIVE CHEMOTHERAPY No dispute reported 06/30/2026 1244112530
Principal investigator 1 Stemline Therapeutics Inc. $149.99 09/01/2025 Non-covered Recipient Entity
Baylor Research Institute
STML-401-0423 - A PHASE II MULTICENTER OPEN -LABEL TRIAL OF TAGRAXOFUSP (TAG) IN COMBINATION WITH VENETOCLAX AND AZACITIDINE (VEN/AZA) IN ADULTS WITH PREVIOUSLY UNTREATED CD123+ ACUTE MYELOID LEUKEMIA (AML) WHO ARE INELIGIBLE FOR INTENSIVE CHEMOTHERAPY No dispute reported 06/30/2026 1244112537
Principal investigator 1 Stemline Therapeutics Inc. $149.99 09/01/2025 Non-covered Recipient Entity
Baylor Research Institute
STML-401-0423 - A PHASE II MULTICENTER OPEN -LABEL TRIAL OF TAGRAXOFUSP (TAG) IN COMBINATION WITH VENETOCLAX AND AZACITIDINE (VEN/AZA) IN ADULTS WITH PREVIOUSLY UNTREATED CD123+ ACUTE MYELOID LEUKEMIA (AML) WHO ARE INELIGIBLE FOR INTENSIVE CHEMOTHERAPY No dispute reported 06/30/2026 1244112542
Principal investigator 1 Stemline Therapeutics Inc. $149.99 09/01/2025 Non-covered Recipient Entity
Baylor Research Institute
STML-401-0423 - A PHASE II MULTICENTER OPEN -LABEL TRIAL OF TAGRAXOFUSP (TAG) IN COMBINATION WITH VENETOCLAX AND AZACITIDINE (VEN/AZA) IN ADULTS WITH PREVIOUSLY UNTREATED CD123+ ACUTE MYELOID LEUKEMIA (AML) WHO ARE INELIGIBLE FOR INTENSIVE CHEMOTHERAPY No dispute reported 06/30/2026 1244112548
Principal investigator 1 Stemline Therapeutics Inc. $149.99 09/01/2025 Non-covered Recipient Entity
Baylor Research Institute
STML-401-0423 - A PHASE II MULTICENTER OPEN -LABEL TRIAL OF TAGRAXOFUSP (TAG) IN COMBINATION WITH VENETOCLAX AND AZACITIDINE (VEN/AZA) IN ADULTS WITH PREVIOUSLY UNTREATED CD123+ ACUTE MYELOID LEUKEMIA (AML) WHO ARE INELIGIBLE FOR INTENSIVE CHEMOTHERAPY No dispute reported 06/30/2026 1244112555
Principal investigator 1 Stemline Therapeutics Inc. $149.99 09/01/2025 Non-covered Recipient Entity
Baylor Research Institute
STML-401-0423 - A PHASE II MULTICENTER OPEN -LABEL TRIAL OF TAGRAXOFUSP (TAG) IN COMBINATION WITH VENETOCLAX AND AZACITIDINE (VEN/AZA) IN ADULTS WITH PREVIOUSLY UNTREATED CD123+ ACUTE MYELOID LEUKEMIA (AML) WHO ARE INELIGIBLE FOR INTENSIVE CHEMOTHERAPY No dispute reported 06/30/2026 1244112562
Principal investigator 1 Stemline Therapeutics Inc. $149.99 09/01/2025 Non-covered Recipient Entity
Baylor Research Institute
STML-401-0423 - A PHASE II MULTICENTER OPEN -LABEL TRIAL OF TAGRAXOFUSP (TAG) IN COMBINATION WITH VENETOCLAX AND AZACITIDINE (VEN/AZA) IN ADULTS WITH PREVIOUSLY UNTREATED CD123+ ACUTE MYELOID LEUKEMIA (AML) WHO ARE INELIGIBLE FOR INTENSIVE CHEMOTHERAPY No dispute reported 06/30/2026 1244112568
Principal investigator 1 Stemline Therapeutics Inc. $149.99 09/01/2025 Non-covered Recipient Entity
Baylor Research Institute
STML-401-0423 - A PHASE II MULTICENTER OPEN -LABEL TRIAL OF TAGRAXOFUSP (TAG) IN COMBINATION WITH VENETOCLAX AND AZACITIDINE (VEN/AZA) IN ADULTS WITH PREVIOUSLY UNTREATED CD123+ ACUTE MYELOID LEUKEMIA (AML) WHO ARE INELIGIBLE FOR INTENSIVE CHEMOTHERAPY No dispute reported 06/30/2026 1244112573
Principal investigator 1 Stemline Therapeutics Inc. $149.99 09/01/2025 Non-covered Recipient Entity
Baylor Research Institute
STML-401-0423 - A PHASE II MULTICENTER OPEN -LABEL TRIAL OF TAGRAXOFUSP (TAG) IN COMBINATION WITH VENETOCLAX AND AZACITIDINE (VEN/AZA) IN ADULTS WITH PREVIOUSLY UNTREATED CD123+ ACUTE MYELOID LEUKEMIA (AML) WHO ARE INELIGIBLE FOR INTENSIVE CHEMOTHERAPY No dispute reported 06/30/2026 1244112579
Principal investigator 1 Stemline Therapeutics Inc. $1,000.00 09/01/2025 Non-covered Recipient Entity
Baylor Research Institute
STML-401-0423 - A PHASE II MULTICENTER OPEN -LABEL TRIAL OF TAGRAXOFUSP (TAG) IN COMBINATION WITH VENETOCLAX AND AZACITIDINE (VEN/AZA) IN ADULTS WITH PREVIOUSLY UNTREATED CD123+ ACUTE MYELOID LEUKEMIA (AML) WHO ARE INELIGIBLE FOR INTENSIVE CHEMOTHERAPY No dispute reported 06/30/2026 1244112585
Principal investigator 1 Stemline Therapeutics Inc. $50.00 08/28/2025 Non-covered Recipient Entity
Baylor Research Institute
STML-401-0423 - A PHASE II MULTICENTER OPEN -LABEL TRIAL OF TAGRAXOFUSP (TAG) IN COMBINATION WITH VENETOCLAX AND AZACITIDINE (VEN/AZA) IN ADULTS WITH PREVIOUSLY UNTREATED CD123+ ACUTE MYELOID LEUKEMIA (AML) WHO ARE INELIGIBLE FOR INTENSIVE CHEMOTHERAPY No dispute reported 06/30/2026 1244112419
Principal investigator 1 Stemline Therapeutics Inc. $2,526.78 08/01/2025 Non-covered Recipient Entity
Baylor Research Institute
STML-401-0423 - A PHASE II MULTICENTER OPEN -LABEL TRIAL OF TAGRAXOFUSP (TAG) IN COMBINATION WITH VENETOCLAX AND AZACITIDINE (VEN/AZA) IN ADULTS WITH PREVIOUSLY UNTREATED CD123+ ACUTE MYELOID LEUKEMIA (AML) WHO ARE INELIGIBLE FOR INTENSIVE CHEMOTHERAPY No dispute reported 06/30/2026 1244112408
Principal investigator 1 Syndax Pharmaceuticals, Inc. $487.50 08/01/2025 Non-covered Recipient Entity
BAYLOR RESEARCH INSTITUTE
A PHASE 1, OPEN-LABEL, DOSE-ESCALATION, AND DOSE-EXPANSION STUDY TO EVALUATE SAFETY, TOLERABILITY, AND CLINICAL ACTIVITY OFSNDX-5613IN COMBINATION WITH INTENSIVE CHEMOTHERAPY IN PARTICIPANTS WITH NEWLY DIAGNOSED ACUTE MYELOID LEUKEMIAS HARBORING ALTERATIONS IN LYSINE-SPECIFIC METHYLTRANSFERASE 2A (KMT2A/MLL), NUCLEOPHOSMIN 1 (NPM1), AND NUCLEOPORIN 98 (NUP98) GENES No dispute reported 06/30/2026 1249050461
Principal investigator 1 Stemline Therapeutics Inc. $975.00 07/30/2025 Non-covered Recipient Entity
Baylor Research Institute
STML-401-0423 - A PHASE II MULTICENTER OPEN -LABEL TRIAL OF TAGRAXOFUSP (TAG) IN COMBINATION WITH VENETOCLAX AND AZACITIDINE (VEN/AZA) IN ADULTS WITH PREVIOUSLY UNTREATED CD123+ ACUTE MYELOID LEUKEMIA (AML) WHO ARE INELIGIBLE FOR INTENSIVE CHEMOTHERAPY No dispute reported 06/30/2026 1244112384
Principal investigator 1 Stemline Therapeutics Inc. $10,421.98 07/30/2025 Non-covered Recipient Entity
Baylor Research Institute
STML-401-0423 - A PHASE II MULTICENTER OPEN -LABEL TRIAL OF TAGRAXOFUSP (TAG) IN COMBINATION WITH VENETOCLAX AND AZACITIDINE (VEN/AZA) IN ADULTS WITH PREVIOUSLY UNTREATED CD123+ ACUTE MYELOID LEUKEMIA (AML) WHO ARE INELIGIBLE FOR INTENSIVE CHEMOTHERAPY No dispute reported 06/30/2026 1244112391
Principal investigator 1 Stemline Therapeutics Inc. $1,000.00 07/30/2025 Non-covered Recipient Entity
Baylor Research Institute
STML-401-0423 - A PHASE II MULTICENTER OPEN -LABEL TRIAL OF TAGRAXOFUSP (TAG) IN COMBINATION WITH VENETOCLAX AND AZACITIDINE (VEN/AZA) IN ADULTS WITH PREVIOUSLY UNTREATED CD123+ ACUTE MYELOID LEUKEMIA (AML) WHO ARE INELIGIBLE FOR INTENSIVE CHEMOTHERAPY No dispute reported 06/30/2026 1244112400
Principal investigator 1 Stemline Therapeutics Inc. $124.80 07/24/2025 Non-covered Recipient Entity
Baylor Research Institute
STML-401-0423 - A PHASE II MULTICENTER OPEN -LABEL TRIAL OF TAGRAXOFUSP (TAG) IN COMBINATION WITH VENETOCLAX AND AZACITIDINE (VEN/AZA) IN ADULTS WITH PREVIOUSLY UNTREATED CD123+ ACUTE MYELOID LEUKEMIA (AML) WHO ARE INELIGIBLE FOR INTENSIVE CHEMOTHERAPY No dispute reported 06/30/2026 1244112367
Principal investigator 1 Stemline Therapeutics Inc. $50.00 07/24/2025 Non-covered Recipient Entity
Baylor Research Institute
STML-401-0423 - A PHASE II MULTICENTER OPEN -LABEL TRIAL OF TAGRAXOFUSP (TAG) IN COMBINATION WITH VENETOCLAX AND AZACITIDINE (VEN/AZA) IN ADULTS WITH PREVIOUSLY UNTREATED CD123+ ACUTE MYELOID LEUKEMIA (AML) WHO ARE INELIGIBLE FOR INTENSIVE CHEMOTHERAPY No dispute reported 06/30/2026 1244112375
Principal investigator 1 Stemline Therapeutics Inc. $50.00 07/18/2025 Non-covered Recipient Entity
Baylor Research Institute
STML-401-0423 - A PHASE II MULTICENTER OPEN -LABEL TRIAL OF TAGRAXOFUSP (TAG) IN COMBINATION WITH VENETOCLAX AND AZACITIDINE (VEN/AZA) IN ADULTS WITH PREVIOUSLY UNTREATED CD123+ ACUTE MYELOID LEUKEMIA (AML) WHO ARE INELIGIBLE FOR INTENSIVE CHEMOTHERAPY No dispute reported 06/30/2026 1244112358
Principal investigator 1 Janssen Research & Development, LLC $75.00 07/14/2025 Non-covered Recipient Entity
BAYLOR SCOTT & WHITE RESEARCH INSTI TUTE
A First in Human Study of the MeninKMT2A MLL1 Inhibitor JNJ75276617 in Participants with Acute Leukemia No dispute reported 06/30/2026 1175403875
Principal investigator 1 Syndax Pharmaceuticals, Inc. $6,626.25 07/11/2025 Non-covered Recipient Entity
BAYLOR RESEARCH INSTITUTE
A PHASE 1, OPEN-LABEL, DOSE-ESCALATION, AND DOSE-EXPANSION STUDY TO EVALUATE SAFETY, TOLERABILITY, AND CLINICAL ACTIVITY OFSNDX-5613IN COMBINATION WITH INTENSIVE CHEMOTHERAPY IN PARTICIPANTS WITH NEWLY DIAGNOSED ACUTE MYELOID LEUKEMIAS HARBORING ALTERATIONS IN LYSINE-SPECIFIC METHYLTRANSFERASE 2A (KMT2A/MLL), NUCLEOPHOSMIN 1 (NPM1), AND NUCLEOPORIN 98 (NUP98) GENES No dispute reported 06/30/2026 1249050417
Principal investigator 1 Syndax Pharmaceuticals, Inc. $487.50 07/07/2025 Non-covered Recipient Entity
BAYLOR RESEARCH INSTITUTE
A PHASE 1, OPEN-LABEL, DOSE-ESCALATION, AND DOSE-EXPANSION STUDY TO EVALUATE SAFETY, TOLERABILITY, AND CLINICAL ACTIVITY OFSNDX-5613IN COMBINATION WITH INTENSIVE CHEMOTHERAPY IN PARTICIPANTS WITH NEWLY DIAGNOSED ACUTE MYELOID LEUKEMIAS HARBORING ALTERATIONS IN LYSINE-SPECIFIC METHYLTRANSFERASE 2A (KMT2A/MLL), NUCLEOPHOSMIN 1 (NPM1), AND NUCLEOPORIN 98 (NUP98) GENES No dispute reported 06/30/2026 1249050415
Principal investigator 1 Stemline Therapeutics Inc. $1,000.00 07/04/2025 Non-covered Recipient Entity
Baylor Research Institute
STML-401-0423 - A PHASE II MULTICENTER OPEN -LABEL TRIAL OF TAGRAXOFUSP (TAG) IN COMBINATION WITH VENETOCLAX AND AZACITIDINE (VEN/AZA) IN ADULTS WITH PREVIOUSLY UNTREATED CD123+ ACUTE MYELOID LEUKEMIA (AML) WHO ARE INELIGIBLE FOR INTENSIVE CHEMOTHERAPY No dispute reported 06/30/2026 1244112338
Principal investigator 1 Stemline Therapeutics Inc. $975.00 07/04/2025 Non-covered Recipient Entity
Baylor Research Institute
STML-401-0423 - A PHASE II MULTICENTER OPEN -LABEL TRIAL OF TAGRAXOFUSP (TAG) IN COMBINATION WITH VENETOCLAX AND AZACITIDINE (VEN/AZA) IN ADULTS WITH PREVIOUSLY UNTREATED CD123+ ACUTE MYELOID LEUKEMIA (AML) WHO ARE INELIGIBLE FOR INTENSIVE CHEMOTHERAPY No dispute reported 06/30/2026 1244112345
Principal investigator 1 Syndax Pharmaceuticals, Inc. $10,920.00 07/01/2025 Non-covered Recipient Entity
BAYLOR RESEARCH INSTITUTE
A PHASE 1, OPEN-LABEL, DOSE-ESCALATION, AND DOSE-EXPANSION STUDY TO EVALUATE SAFETY, TOLERABILITY, AND CLINICAL ACTIVITY OFSNDX-5613IN COMBINATION WITH INTENSIVE CHEMOTHERAPY IN PARTICIPANTS WITH NEWLY DIAGNOSED ACUTE MYELOID LEUKEMIAS HARBORING ALTERATIONS IN LYSINE-SPECIFIC METHYLTRANSFERASE 2A (KMT2A/MLL), NUCLEOPHOSMIN 1 (NPM1), AND NUCLEOPORIN 98 (NUP98) GENES No dispute reported 06/30/2026 1249050413
Principal investigator 1 Stemline Therapeutics Inc. $15,000.00 06/09/2025 Non-covered Recipient Entity
Baylor Research Institute
STML-401-0423 - A PHASE II MULTICENTER OPEN -LABEL TRIAL OF TAGRAXOFUSP (TAG) IN COMBINATION WITH VENETOCLAX AND AZACITIDINE (VEN/AZA) IN ADULTS WITH PREVIOUSLY UNTREATED CD123+ ACUTE MYELOID LEUKEMIA (AML) WHO ARE INELIGIBLE FOR INTENSIVE CHEMOTHERAPY No dispute reported 06/30/2026 1244112256
Principal investigator 1 Stemline Therapeutics Inc. $1,750.00 06/09/2025 Non-covered Recipient Entity
Baylor Research Institute
STML-401-0423 - A PHASE II MULTICENTER OPEN -LABEL TRIAL OF TAGRAXOFUSP (TAG) IN COMBINATION WITH VENETOCLAX AND AZACITIDINE (VEN/AZA) IN ADULTS WITH PREVIOUSLY UNTREATED CD123+ ACUTE MYELOID LEUKEMIA (AML) WHO ARE INELIGIBLE FOR INTENSIVE CHEMOTHERAPY No dispute reported 06/30/2026 1244112271
Principal investigator 1 Stemline Therapeutics Inc. $1,750.00 06/09/2025 Non-covered Recipient Entity
Baylor Research Institute
STML-401-0423 - A PHASE II MULTICENTER OPEN -LABEL TRIAL OF TAGRAXOFUSP (TAG) IN COMBINATION WITH VENETOCLAX AND AZACITIDINE (VEN/AZA) IN ADULTS WITH PREVIOUSLY UNTREATED CD123+ ACUTE MYELOID LEUKEMIA (AML) WHO ARE INELIGIBLE FOR INTENSIVE CHEMOTHERAPY No dispute reported 06/30/2026 1244112288
Principal investigator 1 Stemline Therapeutics Inc. $2,957.50 06/09/2025 Non-covered Recipient Entity
Baylor Research Institute
STML-401-0423 - A PHASE II MULTICENTER OPEN -LABEL TRIAL OF TAGRAXOFUSP (TAG) IN COMBINATION WITH VENETOCLAX AND AZACITIDINE (VEN/AZA) IN ADULTS WITH PREVIOUSLY UNTREATED CD123+ ACUTE MYELOID LEUKEMIA (AML) WHO ARE INELIGIBLE FOR INTENSIVE CHEMOTHERAPY No dispute reported 06/30/2026 1244112297
Principal investigator 1 Stemline Therapeutics Inc. $1,300.00 06/09/2025 Non-covered Recipient Entity
Baylor Research Institute
STML-401-0423 - A PHASE II MULTICENTER OPEN -LABEL TRIAL OF TAGRAXOFUSP (TAG) IN COMBINATION WITH VENETOCLAX AND AZACITIDINE (VEN/AZA) IN ADULTS WITH PREVIOUSLY UNTREATED CD123+ ACUTE MYELOID LEUKEMIA (AML) WHO ARE INELIGIBLE FOR INTENSIVE CHEMOTHERAPY No dispute reported 06/30/2026 1244112304
Principal investigator 1 Stemline Therapeutics Inc. $124.80 06/09/2025 Non-covered Recipient Entity
Baylor Research Institute
STML-401-0423 - A PHASE II MULTICENTER OPEN -LABEL TRIAL OF TAGRAXOFUSP (TAG) IN COMBINATION WITH VENETOCLAX AND AZACITIDINE (VEN/AZA) IN ADULTS WITH PREVIOUSLY UNTREATED CD123+ ACUTE MYELOID LEUKEMIA (AML) WHO ARE INELIGIBLE FOR INTENSIVE CHEMOTHERAPY No dispute reported 06/30/2026 1244112313
Principal investigator 1 Stemline Therapeutics Inc. $4,000.00 06/09/2025 Non-covered Recipient Entity
Baylor Research Institute
STML-401-0423 - A PHASE II MULTICENTER OPEN -LABEL TRIAL OF TAGRAXOFUSP (TAG) IN COMBINATION WITH VENETOCLAX AND AZACITIDINE (VEN/AZA) IN ADULTS WITH PREVIOUSLY UNTREATED CD123+ ACUTE MYELOID LEUKEMIA (AML) WHO ARE INELIGIBLE FOR INTENSIVE CHEMOTHERAPY No dispute reported 06/30/2026 1244112322
Principal investigator 1 Stemline Therapeutics Inc. $3,500.00 06/09/2025 Non-covered Recipient Entity
Baylor Research Institute
STML-401-0423 - A PHASE II MULTICENTER OPEN -LABEL TRIAL OF TAGRAXOFUSP (TAG) IN COMBINATION WITH VENETOCLAX AND AZACITIDINE (VEN/AZA) IN ADULTS WITH PREVIOUSLY UNTREATED CD123+ ACUTE MYELOID LEUKEMIA (AML) WHO ARE INELIGIBLE FOR INTENSIVE CHEMOTHERAPY No dispute reported 06/30/2026 1244112329
Principal investigator 1 Stemline Therapeutics Inc. $124.80 06/05/2025 Non-covered Recipient Entity
Baylor Research Institute
STML-401-0423 - A PHASE II MULTICENTER OPEN -LABEL TRIAL OF TAGRAXOFUSP (TAG) IN COMBINATION WITH VENETOCLAX AND AZACITIDINE (VEN/AZA) IN ADULTS WITH PREVIOUSLY UNTREATED CD123+ ACUTE MYELOID LEUKEMIA (AML) WHO ARE INELIGIBLE FOR INTENSIVE CHEMOTHERAPY No dispute reported 06/30/2026 1244112246
Principal investigator 1 Stemline Therapeutics Inc. $97.50 06/05/2025 Non-covered Recipient Entity
Baylor Research Institute
STML-401-0423 - A PHASE II MULTICENTER OPEN -LABEL TRIAL OF TAGRAXOFUSP (TAG) IN COMBINATION WITH VENETOCLAX AND AZACITIDINE (VEN/AZA) IN ADULTS WITH PREVIOUSLY UNTREATED CD123+ ACUTE MYELOID LEUKEMIA (AML) WHO ARE INELIGIBLE FOR INTENSIVE CHEMOTHERAPY No dispute reported 06/30/2026 1244112263
Principal investigator 1 Stemline Therapeutics Inc. $50.00 06/05/2025 Non-covered Recipient Entity
Baylor Research Institute
STML-401-0423 - A PHASE II MULTICENTER OPEN -LABEL TRIAL OF TAGRAXOFUSP (TAG) IN COMBINATION WITH VENETOCLAX AND AZACITIDINE (VEN/AZA) IN ADULTS WITH PREVIOUSLY UNTREATED CD123+ ACUTE MYELOID LEUKEMIA (AML) WHO ARE INELIGIBLE FOR INTENSIVE CHEMOTHERAPY No dispute reported 06/30/2026 1244112280
Principal investigator 1 Janssen Research & Development, LLC $36,513.00 05/23/2025 Non-covered Recipient Entity
BAYLOR SCOTT & WHITE RESEARCH INSTI TUTE
A First in Human Study of the MeninKMT2A MLL1 Inhibitor JNJ75276617 in Participants with Acute Leukemia No dispute reported 06/30/2026 1175403844
Principal investigator 1 Janssen Research & Development, LLC $20,000.00 05/23/2025 Non-covered Recipient Entity
BAYLOR SCOTT & WHITE RESEARCH INSTI TUTE
A First in Human Study of the MeninKMT2A MLL1 Inhibitor JNJ75276617 in Participants with Acute Leukemia No dispute reported 06/30/2026 1175403897
Principal investigator 1 Syndax Pharmaceuticals, Inc. $29,957.50 05/01/2025 Non-covered Recipient Entity
BAYLOR RESEARCH INSTITUTE
A PHASE 1, OPEN-LABEL, DOSE-ESCALATION, AND DOSE-EXPANSION STUDY TO EVALUATE SAFETY, TOLERABILITY, AND CLINICAL ACTIVITY OFSNDX-5613IN COMBINATION WITH INTENSIVE CHEMOTHERAPY IN PARTICIPANTS WITH NEWLY DIAGNOSED ACUTE MYELOID LEUKEMIAS HARBORING ALTERATIONS IN LYSINE-SPECIFIC METHYLTRANSFERASE 2A (KMT2A/MLL), NUCLEOPHOSMIN 1 (NPM1), AND NUCLEOPORIN 98 (NUP98) GENES No dispute reported 06/30/2026 1249050193
Principal investigator 1 Syndax Pharmaceuticals, Inc. $1,975.00 04/16/2025 Non-covered Recipient Entity
BAYLOR RESEARCH INSTITUTE
A PHASE 1, OPEN-LABEL, DOSE-ESCALATION, AND DOSE-EXPANSION STUDY TO EVALUATE SAFETY, TOLERABILITY, AND CLINICAL ACTIVITY OFSNDX-5613IN COMBINATION WITH INTENSIVE CHEMOTHERAPY IN PARTICIPANTS WITH NEWLY DIAGNOSED ACUTE MYELOID LEUKEMIAS HARBORING ALTERATIONS IN LYSINE-SPECIFIC METHYLTRANSFERASE 2A (KMT2A/MLL), NUCLEOPHOSMIN 1 (NPM1), AND NUCLEOPORIN 98 (NUP98) GENES No dispute reported 06/30/2026 1249050165
Principal investigator 1 Syndax Pharmaceuticals, Inc. $100.00 04/09/2025 Non-covered Recipient Entity
BAYLOR RESEARCH INSTITUTE
A PHASE 1, OPEN-LABEL, DOSE-ESCALATION, AND DOSE-EXPANSION STUDY TO EVALUATE SAFETY, TOLERABILITY, AND CLINICAL ACTIVITY OFSNDX-5613IN COMBINATION WITH INTENSIVE CHEMOTHERAPY IN PARTICIPANTS WITH NEWLY DIAGNOSED ACUTE MYELOID LEUKEMIAS HARBORING ALTERATIONS IN LYSINE-SPECIFIC METHYLTRANSFERASE 2A (KMT2A/MLL), NUCLEOPHOSMIN 1 (NPM1), AND NUCLEOPORIN 98 (NUP98) GENES No dispute reported 06/30/2026 1249050157
Principal investigator 1 Stemline Therapeutics Inc. $165.00 03/03/2025 Non-covered Recipient Entity
Baylor Research Institute
STML-401-0423 - A PHASE II MULTICENTER OPEN -LABEL TRIAL OF TAGRAXOFUSP (TAG) IN COMBINATION WITH VENETOCLAX AND AZACITIDINE (VEN/AZA) IN ADULTS WITH PREVIOUSLY UNTREATED CD123+ ACUTE MYELOID LEUKEMIA (AML) WHO ARE INELIGIBLE FOR INTENSIVE CHEMOTHERAPY No dispute reported 06/30/2026 1244112238
Principal investigator 1 Stemline Therapeutics Inc. $237.62 01/28/2025 Non-covered Recipient Entity
Baylor Research Institute
STML-401-0423 - A PHASE II MULTICENTER OPEN -LABEL TRIAL OF TAGRAXOFUSP (TAG) IN COMBINATION WITH VENETOCLAX AND AZACITIDINE (VEN/AZA) IN ADULTS WITH PREVIOUSLY UNTREATED CD123+ ACUTE MYELOID LEUKEMIA (AML) WHO ARE INELIGIBLE FOR INTENSIVE CHEMOTHERAPY No dispute reported 06/30/2026 1244112212
Principal investigator 1 Stemline Therapeutics Inc. $10.60 01/23/2025 Non-covered Recipient Entity
Baylor Research Institute
STML-401-0423 - A PHASE II MULTICENTER OPEN -LABEL TRIAL OF TAGRAXOFUSP (TAG) IN COMBINATION WITH VENETOCLAX AND AZACITIDINE (VEN/AZA) IN ADULTS WITH PREVIOUSLY UNTREATED CD123+ ACUTE MYELOID LEUKEMIA (AML) WHO ARE INELIGIBLE FOR INTENSIVE CHEMOTHERAPY No dispute reported 06/30/2026 1244112183
Principal investigator 1 Stemline Therapeutics Inc. $100.37 01/23/2025 Non-covered Recipient Entity
Baylor Research Institute
STML-401-0423 - A PHASE II MULTICENTER OPEN -LABEL TRIAL OF TAGRAXOFUSP (TAG) IN COMBINATION WITH VENETOCLAX AND AZACITIDINE (VEN/AZA) IN ADULTS WITH PREVIOUSLY UNTREATED CD123+ ACUTE MYELOID LEUKEMIA (AML) WHO ARE INELIGIBLE FOR INTENSIVE CHEMOTHERAPY No dispute reported 06/30/2026 1244112189
Principal investigator 1 Stemline Therapeutics Inc. $175.82 01/23/2025 Non-covered Recipient Entity
Baylor Research Institute
STML-401-0423 - A PHASE II MULTICENTER OPEN -LABEL TRIAL OF TAGRAXOFUSP (TAG) IN COMBINATION WITH VENETOCLAX AND AZACITIDINE (VEN/AZA) IN ADULTS WITH PREVIOUSLY UNTREATED CD123+ ACUTE MYELOID LEUKEMIA (AML) WHO ARE INELIGIBLE FOR INTENSIVE CHEMOTHERAPY No dispute reported 06/30/2026 1244112195
Principal investigator 1 Stemline Therapeutics Inc. $20.90 01/23/2025 Non-covered Recipient Entity
Baylor Research Institute
STML-401-0423 - A PHASE II MULTICENTER OPEN -LABEL TRIAL OF TAGRAXOFUSP (TAG) IN COMBINATION WITH VENETOCLAX AND AZACITIDINE (VEN/AZA) IN ADULTS WITH PREVIOUSLY UNTREATED CD123+ ACUTE MYELOID LEUKEMIA (AML) WHO ARE INELIGIBLE FOR INTENSIVE CHEMOTHERAPY No dispute reported 06/30/2026 1244112203
Principal investigator 1 Stemline Therapeutics Inc. $4,200.00 01/23/2025 Non-covered Recipient Entity
Baylor Research Institute
STML-401-0423 - A PHASE II MULTICENTER OPEN -LABEL TRIAL OF TAGRAXOFUSP (TAG) IN COMBINATION WITH VENETOCLAX AND AZACITIDINE (VEN/AZA) IN ADULTS WITH PREVIOUSLY UNTREATED CD123+ ACUTE MYELOID LEUKEMIA (AML) WHO ARE INELIGIBLE FOR INTENSIVE CHEMOTHERAPY No dispute reported 06/30/2026 1244112220
Principal investigator 1 Stemline Therapeutics Inc. $46.60 01/23/2025 Non-covered Recipient Entity
Baylor Research Institute
STML-401-0423 - A PHASE II MULTICENTER OPEN -LABEL TRIAL OF TAGRAXOFUSP (TAG) IN COMBINATION WITH VENETOCLAX AND AZACITIDINE (VEN/AZA) IN ADULTS WITH PREVIOUSLY UNTREATED CD123+ ACUTE MYELOID LEUKEMIA (AML) WHO ARE INELIGIBLE FOR INTENSIVE CHEMOTHERAPY No dispute reported 06/30/2026 1244112228